Depression News

News

Depression, diabetes duration predict sexual dysfunction in women with T1D

20230923130000

Type 1 diabetes (T1D) is significantly associated with the risk of sexual dysfunction among women, according to the results of a systematic review and meta-analysis.

Antidepressant use among HCC patients linked to lower risk of death

20230922060000

For patients with hepatocellular carcinoma (HCC), the use of antidepressants after diagnosis may signal increased overall and cancer-specific survival, according to a study.

Zuranolone improves symptoms in adults with major depressive disorder

20230921110000

Treatment with zuranolone 50 mg/day in adults with major depressive disorder (MDD) results in greater improvements in depressive symptoms at day 15, demonstrating a rapid time to effect (day 3), and is generally well tolerated, with no new safety concerns compared with lower dosages, reports a study.

Postpartum depression: Another outcome of the COVID-19 pandemic?

Zuranolone safe, effective for postpartum depression

20230920130000

Use of zuranolone significantly improves depressive symptoms, with no serious side effects, in women with severe postpartum depression (PPD), a common perinatal complication with adverse maternal and infant outcomes, results of a phase III trial have shown.

For older people, hobby engagement can promote mental wellbeing

Jairia Dela Cruz, 20230919140000

Older adults who engage in activities during their leisure time for pleasure appear to be less depressed and are happier and more satisfied with their life in general, as shown in a study.

Vitamin D levels inversely linked to depression in young people

20230918060000

Early adolescents with higher vitamin D levels at baseline appear to be at lower risk of depression, a study has found.

Psilocybin as an antidepressant clears early-phase trial

Jairia Dela Cruz, 20230910140000

A single dose of psilocybin paired with psychological support helps alleviate depressive symptoms and improve functional disability, with sustained effects and no serious adverse events, according to data from a phase II trial.

Depression ups risk of CVD, mortality

Stephen Padilla, 20230908110000

Individuals with depression are at higher risk of developing cardiovascular disease (CVD), which may even result in death, suggests a recent study.

Paternal depression linked to subsequent offspring depression

20230908060000

Children who are exposed to paternal depression are at increased risk of depression, as shown in a study.

Postnatal SSRI treatment helps with postnatal depression–associated problems

20230906060000

Treating postnatal depression with selective serotonin reuptake inhibitors (SSRIs) may be beneficial for both mothers and their children in the long term, with a recent study showing that SSRIs can reduce the risk of several negative outcomes, such as maternal depression and child behavioural problems, according to a study.

NCDs in Focus Act Now! Summit 2022

16 Mar 2023

Viatris, a global healthcare company, collaborated with the Thai Hypertension Society and the Thai NCD Collaboration Group to organize the NCDs in Focus Act Now! Summit 2022 in Bangkok on October 29^th and 30^th. This summit brought together nearly 300 multidisciplinary experts from Southeast Asia and India to address the unmet needs in managing two critical noncommunicable diseases (NCDs): cardiovascular diseases (CVDs) and mental health disorders (MHDs) in the region.

The summit had several key objectives. Firstly, it highlighted the effectiveness of clinical data in addressing gaps and unmet needs in clinical practice. Secondly, it emphasized the importance of sharing expertise and best practices through a platform that can optimize patient care. Additionally, it discussed the challenges of cardiovascular disease and mental health disorder care in a post COVID-19 world, and the need to re-examine them.

The summit also offered valuable insights into policy and practice changes, as well as innovative digital solutions that can lead to better outcomes. Lastly, it emphasized the significance of gaining a deeper understanding of the gaps in the patient journey to enhance patient care further.

Overall, the NCDs in Focus Act Now! Summit 2022 was a highly informative and productive event, with experts collaborating to improve the management of CVDs and MHDs in Southeast Asia and India.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.